Journal of immunotherapy.
`y 31, no. 9 (Nov-Dec 2008)
`¢ Bet-oleetion
`
`BER-DECEMBER 2008
`
`marnat rat
`OVID
`
`“OFFICIAL rereOF ng as roy
`:Breerrerte THERAPYOFCANCER
`
`neTelaa3Wilkins
`
`WEB-BASED MANUSCRIPT
`
`SUBMISSION NOW AVAILABLE!
`See journal Web site for details.
`www.immunotherapy-journal.com
`
`PROPERTYOF THE
`NATIONAL
`LIBRARY OF
`MEDICINE
`
`ce igCee :
`
`Miltenyi Ex. 1017 Page 1
`
`

`

`JOURNAL OF
`
`Immunotherapy
`
`OFFICIAL JOURNAL OF INTERNATIONAL SOCIETY
`FOR BIOLOGICAL THERAPY OF CANCER
`
`EpIToR-IN-CHIEF
`Steven A. Rosenberg, M.D., Ph.D.
`Bethesda, Maryland
`
`ASSOCIATE EDITORS
`
`Michael B. Atkins, M.D.
`Patrick Hwu, M.D.
`Michael T. Lotze, M.D.
`Francesco Marincola, M.D.
`James J. Mulé, Ph.D.
`Nicholas P. Restifo, M.D.
`
`EpITORIAL COORDINATOR
`Hannah Lee
`Phone: 215-253-3551
`Fax: 215-220-3450
`email: journalofimmunotherapy@gmail.com
`
`
`
`INTERNATIONAL SOCIETY FOR BIOLOGICAL
`THERAPY OF CANCER
`Tara Withington, Executive Director
`555 E, Wells Street
`11th Floor
`Milwaukee, WI 53202-3823
`Tel: (414) 271-2456; fax: (414) 276-3349
`email: info@isbtc.org
`
`
`PUBLICATION STAFF
`David Myers, Publisher
`Jonathan Pine, Senior Executive Editor
`
`VOL. 31, NO. 9, November—December 2008
`
`EprroriAL BOARD
`Michael Atkins
`
`Richard Barth
`
`Ernest Borden
`
`Alfred Chang
`Robert O. Dillman
`
`MaryL.Disis
`Janice P. Dutcher
`
`Alexander Eggermont
`Soldano Ferrone
`BernardA. Fox
`
`Michael 8. Gordon
`
`Ronald B. Herberman
`
`Peter Hersey
`Yutaka Kawakami
`
`Ulrich Keilholz
`
`Steven K. Libutti
`
`Albert F. LoBuglio
`Kim A. Margolin
`James Lee Murray
`Elizabeth A. Repasky
`Licia Rivoltini
`
`Pedro Romero
`
`MichaelSalgaller
`Noriyuki Sato
`Carmen Scheibenbogen
`Craig L. Slingluff, Jr.
`Paul M.Sondel
`
`Mario Sznol
`
`Walter Urba
`
`Louis Weiner
`
`Christine A. White
`
`Jon M. Wigginton
`
`Foradvertising inquiries, please contact Sherry Reedat sherry.reed@wolterskluwer.com, 410-528-8553.
`
`Miltenyi Ex. 1017 Page 2
`
`Miltenyi Ex. 1017 Page 2
`
`

`

`
`
`Journal
`
`
`
`of Immunotherapy November—December 2008
`
`Volume 31
`
`Number 9
`
`Contents
`
`Review Article
`
`793 Dendritic Cells: A Critical Player in Cancer Therapy?
`Anna Karolina Palucka, Hideki Ueno, Joseph Fay, and Jacques Banchereau
`
`Clinical Studies
`
`806 Donor Regulatory T Cells Identified by FoxP3 Expression but Also by the
`Membranous CD4* CD127°°*/"** Phenotype Influence Graft-versus-tumor
`Effect After Donor Lymphocyte Infusion
`Yosr Hicheri, Abdelghani Bouchekioua, Yamina Hamel, Adeline Henry,
`Heléne Rouard, Cécile Pautas, Jean-Louis Beaumont, Mathieu Kuentz,
`Catherine Cordonnier, José L. Cohen, and Sébastien Maury
`
`812 A Phase 1/2 Study of Autologous Neuroblastoma Tumor Cells Genetically Modified
`to Secrete IL-2 in Patients With High-risk Neuroblastoma
`Heidi V. Russell, Douglas Strother, Zhuyong Mei, Donna Rill, Edwina Popek,
`Ettore Biagi, Eric Yvon, Malcolm Brenner, and Raphael Rousseau
`
`820 An MVA-based Vaccine Targeting the Oncofetal Antigen 5T4 in Patients
`Undergoing Surgical Resection of Colorectal Cancer Liver Metastases
`Eyad Elkord, Adam Dangoor, Noel L. Drury, Richard Harrop, Deborah J. Burt,
`Jan W. Drijfhout, Caroline Hamer, Danielle Andrews, Stuart Naylor,
`David Sherlock, Robert E. Hawkins, and Peter L. Stern
`
`(continued next page)
`
`Journal of Immunotherapy (ISSN: #1524-9557) is published nine times a year in January, February. April, May, June,
`July, September, October, and November by Lippincott Williams & Wilkins, 16522 Hunters Green Parkway.
`Hagerstown, MD 21740-2116. Business and production offices are located at 530 Walnut Street, Philadelphia. PA
`19106-3621. Periodicals postage paid at Hagerstown, MD and at additional mailing offices. Copyright © 2008 by
`Lippincott Williams & Wilkins.
`Annual Subscription Rates: United States - $600 Individual, $1585 Institution, $282 In-training. Rest of World - $700
`Individual, $1867 Institution, $296 In-training. Single copy rate $206. All prices include a handling charge. Subscriptions
`outside of North America must add $14 forairfreight delivery. United States residents of AL, CO, DC, FL, GA, HI, IA,
`ID, IN, KS, KY, LA, MD, MO, ND, NM. NV, PR, RI. SC, SD, UT, VT, WA, WVaddstate sales tax. The GST tax of
`7% must be added to all orders shipped to Canada (Lippincott Williams & Wilkins’ GST Identification #895524239,
`Publications Mail Agreement #616346. Subscription prices outside the United States must be prepaid. Prices subject to
`change without notice. Visit us online at www.lww.com.
`Postmaster: Send address changes to Journal of Immunotherapy, P.O. Box 1550, Hagerstown, MD 21740.
`
`Miltenyi Ex. 1017 Page 3
`
`a
`‘
`_ Lippincott
`Williams & Wilkins
`Wolters Kluwer
`
`.
`
`
`
`Miltenyi Ex. 1017 Page 3
`
`

`

`Journal of Immunotherapy « Volume 31, Number 9, November-December 2008
`
`Con te nts (continued)
`
`830
`
`840
`
`849
`
`Clinical-scale Lentiviral Vector Transduction of PBL for TCR Gene Therapy
`and Potential for Expression in Less-differentiated Cells
`Shicheng Yang, Steven A. Rosenberg, and Richard A. Morgan
`
`Tumor Antigen-specific T-cells are Present in the CD80x~ T-cell
`Effector-memory Pool
`Isabelle Magalhaes, Nalini Kumar Vudattu, Elke Jdger, and Markus J. Maeurer
`
`Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination
`With NY-ESO-1 Protein Plus BCG and GM-CSF
`Padmanee Sharma, Dean F. Bajorin, Achim A. Jungbluth, Harry Herr,
`Lloyd J. Old, and Sacha Gnjatic
`
`Basic Studies
`
`858
`
`871
`
`885
`
`896
`
`Anisomycin Inhibits the Behaviors of T cells and the Allogeneic
`Skin Transplantation in mice
`Feiyue Xing, Zhe Yu, Jing Liu, Jingfang Di, Shan Zeng, Di Chen, Ling Chen,
`Zhiyuan Fang, Zhongfeng Guo, Shan Pan, Jiongkun Wang, Yuting Li, Wenting Hao,
`Zhenhua Fan, Zhenping Teng, Guoliang Chen, Zhencheng Chen, Chengquan Mao,
`Yutian Long, and Na Liu
`
`A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced
`Immune Effector Functions for Human Leukemic Cells
`Christian Kellner, Joerg Bruenke, Julia Stieglmaier, Michael Schwenmlein,
`Michael Schwenkert, Heiko Singer, Kristin Mentz, Matthias Peipp, Peter Lang,
`Fuat Oduncu, Bernhard Stockmeyer, and Georg H. Fey
`
`Intratumoral Dendritic Cells and Chemoradiation for the Treatment of Murine
`Squamous Cell Carcinoma
`Jeffrey S. Moyer, Ji Li, Shuang Wei, Seagal Teitz-Tennenbaum,
`and Alfred E. Chang
`
`Immune Response of Human Propagated y5-T-Cells to Neuroblastoma Recommend
`the Vé1* Subset for y5-T-cell-based Immunotherapy
`Karin Schilbach, Klaus Frommer, Sybille Meier, Rupert Handgretinger,
`and Matthias Eyrich
`
`906
`
`Combined Anti-CD40 Conditioning and Well-timed Immunization Prolongs
`CD8* T Cell Accumulation and Control of Established Brain Tumors
`Christina M. Ryan, Kevin Staveley-O’Carroll, and Todd D. Schell
`
`(continued next page)
`
`Miltenyi Ex. 1017 Page 4
`
`Miltenyi Ex. 1017 Page 4
`
`

`

`Journal of Immunotherapy * Volume 31, Number 9, November-December 2008
`
`Co ntents (continued)
`
`Abstracts
`
`921 Abstracts for the 23rd Annual Scientific Meeting of the International Society for
`Biological Therapy of Cancer
`
`972 Author Index
`
`
`
`This journalis listed in Index Medicus)MEDLINE Current Contents/Life Sciences Scisearch,
`Biomedical Database, BIOSIS, EMBASE]/Excerpta Medica, Chemical Abstracts, and Current Awarness in Biological Sciences.
`
`Address for non-member subscription information, orders, or change of address: Lippincott Williams & Wilkins, P.O. Box 1580, Hagerstown,
`MD 21741-1580; phone 800-638-3030 (outside the United States 301-223-2300); fax 301-223-2400. In Japan, contact LWW Igaku-Shoin Ltd., 3-23-14
`Hongo, Bunkyo-ku, Tokyo 113-0033; phone 81-3-5689-5400;
`fax 81-3-5689-5402.
`In Bangladesh,
`India, Nepal, Sri Lanka, and Pakistan,
`contact Globe Publications Pvt. B-13 3rd Floor, A Block, Shopping Complex, Naraina Vihar, Ring Road, New Delhi, 110028; phone 91-11-579-3211;
`fax 91-11-579-8876.
`
`Lippincott Williams & Wilkins cannot be held responsible for errors or for any consequences arising from the use of the information contained in this
`journal. The appearance ofadvertising in this journal does not constitute an endorsementor approval by Lippincott Williams & Wilkins for the quality
`or value of the product advertised or of the claims made for it by its manufacturer.
`
`PERMISSION TO PHOTOCOPY ARTICLES:This publication is protected by copyright. Permission to photocopy must be secured in writing from:
`Permission Dept., Lippincott Williams & Wilkins. 351 West Camden Street, Baltimore, MD 21201, FAX: 410-528-8550; or Copyright Clearance
`Center (CCC), 222 Rosewood Dr., Danvers, MA 01923; FAX: 508-750-4470; or UMI, Box 49, 300 North Zeeb Road, Ann Arbor, MI 48106-1346;
`FAX: 313-761-1203.
`
`
`Article and issue photocopies and 16-mm microfilm, 35-mm microfilm, and 105-mm microfiche are available from UMI, 300 North Zeeb Road,
`Ann Arbor, MI 48106-1346.
`
`Miltenyi Ex. 1017 Page 5
`
`Miltenyi Ex. 1017 Page 5
`
`

`

`
`
`This material may be protected by Copyright law (Title 17 U.S. Code)
`
`Abstracts
`
`J Immunother * Volume 31, Number 9, November-December 2008
`
`adverse events were noted. None of the 10 patients achieved partia]
`remission; 4 patients achieved stable disease. Thirteen of the 16 patients
`receiving | x 10° DC developeda strong positive skin reaction to tumor
`lysates. In 6 patients, positive skin reaction to tumor lysates was shown
`to be maintained in 6 months after the development of the positive skin
`reaction to tumor lysates. The correlation of DTH responses to tumor
`lysates in vivo with immune responses to lysates in vitro and clinical
`responses was evaluated. Patients with a positive DTH to tumorlysates
`revealed the increase in the number of peripheral blood lymphocytes
`(PBL) compared to those with a negative DTH. Theincrease in the
`number of the T cells in PBL was observed in patients with a positive
`DTH. Furthermore, patients with a positive DTH revealed the
`significant interferon-y production by T cells stimulated with TP-DC,
`The duration of the positive DTH was within 6 months after the final
`treatment correlated with the decrease in the number of PBL in vivo and
`the decrease of the production of interferon-y in vitro by T cells. The
`results ofthis phase | trial appear promising for further development in
`patients with advanced gastrointestinal cancers.
`
`
`
`Phase II Trial of Combination Therapy of Tumor Lysate-pulsed
`Dendritic Cells and Adoptive Transfer of Anti-CD3 Activated T
`Cells (ATVAC)
`to Lower Postsurgical Recurrence Rates of
`Cholangiocellular Carcinoma (CCC)
`Koichi Shimizu'**, Nobuhiro Takeshita?, Yoshihito Kotera’, Kenji
`Yoshitoshi*, Syunichi Ariizumi”, Satoshi Katagiri?, Yoshihito Otsubo-,
`Keishi Tanigawa7?, Ken Takasaki??, Masakazu Yamamoto’,
`Atsushi Aruga??. ‘Chemoimmunotherapy Center, Shin-Itabashi Clinic;
`“Department of Gastroenterology, Tokvo Women's Medical University
`(TWMU); 77. B. Therapeutics Ine, Tokyo, Japan.
`Background: Postsurgical
`recurrence of cholangiocellular carcinoma
`(CCC) is frequent and fatal. Patients with CCC who underwentcurative
`resection revealed the median overall survival (OS) of 21 months [95%
`confidence interval (CI), 11.6-30.4]. This phase II study investigated the
`efficacy and safety of adoptive transfer of anti-CD3 activated Tcells
`(ATVAC) in patients who underwent curative resection for CCC to
`lower postsurgical recurrence rates.
`Methods: Patients with CCC who underwent curative resection received
`ATVAC. ATVACconsisted of dendritic cells with autologous lympho-
`cytes activated with interleukin-2 and antibody to CD3 at 7-day or
`Intratumoral Injection of Immature Dendritic Cells (DCI) Against
`14-day intervals for 3 months. The immune responses to tumor antigens
`Gastrointestinal (GI) Cancers: A Phase I Study in Patients With
`(Tgs) were monitored by delayed-type hypersensitivity (DTH). The
`Metastatic GI Cancers
`primary end point was relapse-free survival. Secondary end points were
`Keishi Shimizu!—ToshimiTanigawa'*, Koichi Fujisawa’,
`
`
`
`
`OS, the monitoring of immune responses to Tgs, and toxicity,
`Results: Between September 2000 and August 2005, 38 patients were
`Nobuhiro Takeshita!, Ken Takasaki!?, Masakazu Yamamoto!,
`included, with a median age of 63.2 years (39 to 81), a median tumorsize
`Atsushi Aruga!. ‘Department of Surgery, Institute of Gastroenterology,
`of 5.7cem. Thirty-eight patients (100%) underwent segmentectomy. On
`Tokyo Women’s Medical University; *J. B. Therapeutics Ine; 7Chema-
`the pathologic findings, vascular invasions, intrahepatic metastases, and
`immunotherapy Center, Shin-Itabashi Clinic, Tokyo, Japan.
`lymph node involvements were 81.1%, 29%, and 55.3%, respectively.
`We have previously shown that direct injection of immature dendritic
`The median relapse-free survival was 14 months (95% CI, 3-25). The
`cells (DCI) into tumor nodules could result in significant remission of
`median OS was 26 months (95%CI, 6-46). 20 patients showed positive
`established subcutaneous tumor. Wetherefore sought to determine DC]
`DTHresponses to Tgs. Among these patients, the median OS was 72
`for cancer treatment, Monocyte-derived DCs were generated in serum-
`months. In contrast, in the group ofpatients with a negative DTH, the
`free medium containing granulocyte macrophage-colony stimulating
`median OS was 13 months (95% CI, 9-17).
`factor (100ng/mL) and interleukin-4 (50ng/mL). Immature, unpulsed
`Conclusions: This result suggests that ATVAC isveryeffective in patients
`DCs were resuspended in ImL ofsaline. Patients received DCI into
`with positive DTH responses to Tgs who underwent curative resection
`tumor nodules 4 times, 14 days apart. In some cases, patients underwent
`for CCC to lower postsurgical recurrence rates.
`systemic administration of interleukin 2 intravenously at 350,000TU
`bodydaily for 4 days consecutively after each DCI. The safety as well
`as the biological andthe clinical effects of DCI were evaluated in a phase
`I clinical trial in patients with metastatic gastrointestinal cancers. Sixteen
`patients have been included, which had evaluable metastatic or
`unresected tumor resistant
`to the conventional chemotherapy/radio-
`therapy. DCI was well tolerated, the major adverse events being fever
`were low grade (grade | and grade 2) with no grade 3 and 4 adverse
`events. The number of DCs administered ranged from | to 20 x 107 cells
`originally generated from 4 cycles of leakapheresis products. One ofthe
`16 patients achieved partial remission (6 mo), 12 achieved stable disease.
`All of these 13 patients developed strong positive skin reaction to
`keyhole limpet hemocyanin. Considering the late stage and progression
`of gastrointestinal cancers,
`the results of
`this phase |
`trial are
`encouraging and promising clinical benefit in patients with chemother-
`apy/radiation-resistant tumors.
`
`
`
`A Phase I/II Trial of Combination Therapy of Tumor Lysate-
`pulsed Dendritic Cells and Adoptive Transfer of Anti-CD3
`Activated T Cells (ATVAC)in Patients With Advanced Gastro-
`intestinal (GI) Cancers
`Koichi
`Shimizu'?*, Keishi Tanigawa**, Nobuhiro Takeshita’,
`Toshimi
`Fujisawa*, Ken Takasaki*?, Masakazu Yamamoto’,
`Atsuhi Aruga’.
`‘Chemoimmunotherapy Center, Shin-Itabashi Clinic,
`“Department of Gastroenterological Surgery, Tokye Women’s Medical
`University (TWMU); 7. B. Therapeutics Inc, Tokyo, Japan.
`We have previously shown that
`tumor lysate-pulsed dendritic cell
`vaccination (TP-DC) elicited therapeutic rejection of established tumor
`in animal models. In addition, combination of TP-DC with administra-
`tion of activated T cells elicited more significant therapeutic rejection of
`established tumor than the single therapy alone in animal models. We,
`therefore sought
`to examine the therapeutic potency of TP-DC with
`administration of anti-CD3 activated T cells (CAT) against gastro-
`intestinal cancers: 3 patients were diagnosed with pancreatic cancer, 7
`patients with HCC, 3 patients with intrahepatic cholangiocarcinoma, 2
`patients with esophageal sarcoma, 12 patients with colorectal cancer.
`Monoeyte-derived DCs were generated in serum-free medium containing
`granulocyte macrophage-colony stimulating factor (100ng/mL) and
`interleukin-4 (SO ng/mL), Patients received TP-DC intradermally4 times
`every 3 weeks with CAT activated with interleukin-2 and antibody to
`CD3: 4 patients received | x 106 DC. 7 received 2x 107, 16 received
`1 x 10°. The safety as well as the biologic and theclinical effects of
`adoptive transfer of anti-CD3 activated T cells (ATVAC) were studied.
`Twenty-seven patients were
`included. Ten of
`these patients had
`evaluable unresected tumor resistant
`to conventional chemotherapy.
`ATVAC was well tolerated; the major adverse events being fever and
`skin erythema of low grade (grade 1 and grade 2). No grade 3 and 4
`
`The CD19 Chimeric Antigen Receptor Re-directs CMVSpecific T
`Cells Derived From Central MemoryT Cells (Bi-specific T Cells)
`Against Human Acute Lymphoid Leukemia (ALL)
`Xiuli Wang, Winnie Wong, Wen-Chung Chang, Julie R. Ostberg,
`David DiGiusto, Michael C. Jensen. Cancer Immunotherapeuties and
`Tumor Immunology, BRI, City of Hope National Medical Center, Duarte,
`CA.
`One strategy to enhance the efficacy of antitumor adoptive T-cell
`therapy is to generate bi-specific T cells, which co-express viral-specific
`and tumor-specific antigen receptors. The hypothesis is
`that
`these
`bi-specific T cells will have enhanced antitumor function in a patient
`through the coordinate stimulation by viral antigens that are presented
`in the context of endogenous professional antigen presenting cells.
`Central memory T cells (Tem) have a unique ability to self-renew.
`proliferate, and differentiate into effector Tem, which suggests that this
`T-cell subset will be mosteffective and persistent upon adoptive transfer.
`
`* RuloneeddtBayete
`
`926
`
`Miltenyi Ex. 1017 Page 6
`
`

`

`| Immunother * Volume 31, Number 9, November—December 2008
`
`Abstracts
`
`Thus, we first selected Tem using the Dreg56 (anti-CD62L) biotinylated
`antibody and CliniMacs
`selection. The purified Tem were
`then
`stimulated twice with cytomegalovirus (CMV) pp65 protein, resulting
`in 40% enrichment of CMV pp65 tetramer+ cells. The CMV-specific
`T cells were expanded more than 1000-fold following a
`single
`restimulation in
`rapid expansion medium,
`and then genetically
`redirected to target CD19 on acute lymphoid leukemia through lentiviral
`transduction with a CD19-specific chimeric antigen receptor, CD19R.
`Upon further stimulation and expansion of these T cells, expression of
`both the CD19R transgene and the endogenous CMV-specific T-cell
`receptor were stable as detected by flow cytometry and/or Western.
`Cytotoxicity assays revealed that the bi-specific T cells could efficiently
`and specifically kill CMV+ targets as well as the acute lymphoid
`leukemia cell
`line SupB15. Together,
`these results suggest
`that
`the
`generationof bi-specific T cells is a feasible strategy with the potential to
`enhance the overall antitumor potential of adoptively transferred T cells.
`
`
`‘Oncology, Unit of Immuno-Biotherapy of Solid Tumors; 7Stem Cell
`Research Institute, San Raffaele Foundation Scientific Institute, Milan,
`ftaly; 7Hillman Cancer Center, University of Pittsburgh Cancer Institute,
`Pittsburgh, PA.
`Cancer Stem cells (CSCs) represent the most aggressive component of
`tumors and have been proposed aselective cellular target in the context
`of biological therapies such as immunotherapy. The main objectives of
`our project are represented by the identification of markers with
`immunological relevance expressed by CSCs andthe validation of their
`role as target molecule to design immunotherapeutic protocols for
`glioblastoma (GBM).
`We carried out a set of experiments using IF and cytofluorimetric or
`confocal microscopy analysis aimed at the immunological characteriza-
`tion of CSCsisolated from human GBM andin vitro cultured either in
`the presence or absence of mitogens. We found that GBM CSCs were
`negative or weakly positive for the expression of MHC classI orclass I
`molecules, with only 1 out of 8 GBM CSClines expressing high level of
`HLA molecules. Along this line, NKG2D ligands (MICA/B or ULBPs)
`Isolating High-affinity T-cell Receptors for Adoptive Therapy of
`were weakly or not expressed by most GBM CSCswith only1 cell line
`Tumors
`being positive for all these molecules while significant expression ofthese
`molecules was detected on GBM tumorcell lines [grown in vitro under
`Susanne Wilde', Bernhard Frankenberger', Daniel Sommermeyer’,
`standard culture conditions (FBS)]. Moreover, defective expression of
`
`
`
`Wolfgang Uckert?, Milosevic',—StefaniSlavoljub Spranger!,
`MHCantigen processing machinery (APM) by GBM CSClines was
`
`Heike H.—Busch’,Pohla**, Matthias Schiemann®, Dirk
`
`
`
`observed. Up-regulation of MHCclass I and of most of APM molecules
`Dolores J. Schendel!*.
`‘Institute of Molecular
`Immunology; ?Max-
`was achieved after interferon (IFN)-y treatment of CSCs, while weak or
`Delbrueck-Center for Molecular Medicine, Berlin, Germany; 7Institute of
`no modulation of MHC class II molecules was observed. Heterogeneous
`Molecular Immumology and Clinical Coaperation Group Immune Mon-
`expression of MHC molecules or NKG2D ligands wasalso observed in
`itoring, Helmholtz Zentrum Miinchen, German Research Center for
`tumors generated byintracranial or subcutaneous transplantation of
`Environmental Health; *Laboratory of Tumor Immunology, LIFE-Center,
`GBM CSCsin immunodeficient mice. Notably, cancer-testis TAAs, such
`Ludwig-Maximilians-University; “Institute of Microbiology, Immunology
`as NY-ESO or MAGE was weaklyor not expressed by GBM CSC lines
`and Hygiene, Technical University Munich, Munich, Germany.
`while survivin and COA-1 were detected in all these cell lines (N = 8).
`If one wants to obtain high-avidity T cells specific for tumor-associated
`Wecarried out in vitro stimulation of peripheral blood mononuclear
`antigens (TAA), one has to deal with the problem that such TAA often
`cells isolated from 2 GBM patients with autologous CSCs and the
`represent self-peptides derived from overexpressed proteins presented by
`specific reactivity of T lymphocytes against GBM CSCs was evaluated
`selfMHC molecules. T cells with high-affinity T-cell receptors (TCR)
`by IFN-y release (enzyme-linked immunosorbent spot) or cytotoxic
`specific for such ligands have been eliminated through the process of
`activity (CD107a mobilization). We found that GBM CSCs, following
`negative selection during lymphocyte development
`to prevent auto-
`IFN-y treatment, can elicit an efficient CSC-specific T-cell-mediated
`immunity. Therefore, TCR affinity of remaining lymphocytes for such
`immune response.
`self-peptides is low. To efficiently generate peptide-specific T cells bearing
`Taken together, these results indicate that MHC molecules and NKG2D
`high-affinity TCR one can tap a nonselected T-cell repertoire when the
`ligands are expressed heterogeneously by both in vitro established CSC
`TAA peptides are presented by allogeneic MHC molecules. Several
`lines and in tumors transplanted in immunodeficient mice. In addition,
`approaches have been used to obtain such allo-restricted, peptide-specific
`though the expression of APM is defective in these cells, we found that
`T-cell clones. We concentrated on dendritic cell
`(DC) priming and
`GBM CSCs can be exploited to generate T-cell-mediated immune
`developed a method using RNA-loaded DCas antigen-presenting cells to
`responses in at least some GBM patients.
`tap unselected T-cell repertoires. For proof of principle, we compared
`self-restricted and allo-restricted priming using tyrosinase as a mode] TAA.
`Self-restricted, peptide-specific T-cell clones from healthy HLA-A2+
`donors were derived using autologous
`tyrosinase-RNA-pulsed DC
`whereasallo-restricted T-cell clones from healthy HLA-A2— donors were
`obtained using autologous DC loaded with RNA encoding tyrosinase
`and allo-HLA-A2 molecules. We demonstrated that allo-restricted T cells
`showed functional superiority and higher functionalavidities. We extended
`these findings by generatingallo-restricted, high-avidity T cells specific for
`a Mart-1 peptide and a survivin peptide to showuniversal application.
`Since adoptive transfer of TCR-transduced peripheral blood lymphocytes
`(PBL) provides a newtherapeutic treatment our aim was to generate TCR-
`transgenic PBL using cloned TCR sequences. To this end, we transduced
`PBLofhealthy donors with self-restricted and allo-restricted sequences of
`tyrosinase-specific T-cell clones with highest functional avidity and best
`capacity to kill
`tumors. The allo-restricted TCR-transduced PBL
`recognized lower peptide concentrations and therefore showed higher
`functional avidity compared with the self-restricted TCR-transduced PBL,
`demonstrating the superiority of the allo-restricted TCR.
`
`
`
`Upregulation of Stem Cell-related Genes in Hypoxic Mammo-
`sphere Cultures
`'Department of
`Norazizah Shafee', Shu-Yuan Liao’, Eric J. Stanbridge*.
`Microbiology, Faculty of Biotechnology and Biomolecular Sciences,
`Universiti Putra Malaysia, Serdang, Malaysia; -Department of Micro-
`biology and Molecular Genetics, University of California, Irvine, CA.
`Nonadherent mammosphere cultures have been used as a method for
`expansion and maintenance of mammarygland stem cells in vitro. We
`have observed that mammospheres cultured in hypoxic condition
`survived better and could be maintained at higher passage numbers
`compared to normoxic conditions. We sought to examine the possible
`involvement of stem cell regulatory genes in the maintenance of these
`mammospheres under hypoxic conditions. We dissociated cells from
`normalas well as breast cancer samples, and cultured them in suspension
`conditions either under normoxia or hypoxia (0.5% Q5). At 20,000 cells/
`ml concentration, only 6 out of 8 samples tested formed mammospheres
`after 7 to 10 days of culture. The number of these primary mammo-
`spheres varies from sample to sample. There was no difference in the
`numbers when cells from the same sample were incubated under hypoxic
`or normoxic conditions. Following formation of the primary mammo-
`spheres, we dissociated and subcultured them at similar cell concentra-
`tions. These mammospheressurvived variable passage numbers, ranging
`from 2 to 10 passages. Mammospheres from sample number 9 showed
`the highest passage number. To investigate the level of stem cells
`
`CANCER STEM CELLS AND THE
`HOST RESPONSE
`
`
`Characterization of the Immune Profile of Cancer Stem Cells
`Isolated From Human Glioblastoma
`.
`~
`2
`.
`-
`“
`*
`Cristina Macealli', Stefania Mazzoleni*, Samantha Scaramuzza',
`Gloria Sovena!. Soldano Ferrone’, Rossella Galli*, Parmiani Giorgio!.
`
`© 2008 Lippincott Williams & Wilkins
`
`927
`Miltenyi Ex. 1017 Page 7
`
`Miltenyi Ex. 1017 Page 7
`
`

`

`JOURNAL OF IMMUNOTHERAPY
`
`A
`
`Abe, Fuminori, 967
`Aboussekhra, Abdelilah, 963
`Ahn, Yong-Oon, 961
`Aichele, Peter, 953
`Aikawa, Elena, 931
`Akporiaye, Emmanuel, 937
`Al-Tweigeri, Taher, 963
`Alber, Sean, 933, 965
`Alderson, Kory, 934, 957
`Allison, James, 934
`Amin, Asim, 933
`Amoscato, Andrew, 965
`Ancarani, Valentina, 935
`Andersen, Mads, 940, 943, 950
`Andrade Filho, Pedro, 940
`Andrea, Beatty. 935
`Apostolou, Irina, 956
`Arbour, Nathalie, 963
`Arizumi, Syunichi, 926
`Armant, Myriam, 921
`Arthur, Cora, 952
`Aruga, Atsushi, 926
`Ascarateil, Stephane, 939
`Asemissen, Anne Marie, 943
`Assi, Hazem, 933
`Atkins, Michael, 931, 958
`Awasthi, Sanjay, 931
`Awasthi, Yogesh, 931
`
`
`Bach, Patricia, 953
`Back, Tim, 934
`Badie, Behnam, 921
`Bek Sorensen, Rikke, 940
`Baeuerle, Patrick, 971
`Baier, Gottfried, 941
`Balint, Klara, 963
`Banat, Gamal, 961
`Baoying, Fang, 928, 929
`Barchetti, Andrea, 963
`Barhoush, Eman, 963
`Bartlett, David, 942, 946
`Baseler, Michael, 938
`Baskar, Sivasubramanian, 969
`Bassie, Rahmatu, 924
`Bauer, Sandra, 943
`Baur, Andrea, 948
`Beatty, Andrea, 935, 948
`Bechmann, Christian, 951
`Becker, Jurgen, 940
`Becker, Maria, 954
`Belisle, Jennifer, 964
`Berezovskaya, Alla, 921
`Berglin, Jon, 948
`Bergmann, Christoph, 921
`Berk, Errik, 942
`Berman, David, 933
`Besselsen, David. 937
`Best, J, 960
`Bhasin, Manoj, 958
`Bhatia, Shailender, 928
`Black, Keith, 928
`
`G72
`
`Abstract Author Index
`
`Blankenstein, Thomas, 948
`Blohm, Ulrike, 953
`Blois, Joe, 931
`Boasberg, P, 970
`Bocchetta, Maurizio, 932, 962
`Bondarenko, Igor, 937
`Bonhoure, Fabien, 939
`Bot, Adrian, 950
`Bouchlaka, Myriam, 934, 939,
`957
`Boyiadzis, Michael, 961
`Bradley-Dunlop, Deborah, 937
`Brandl, Anja, 971
`Brandl, Christian, 971
`Bray, Sarah, 939
`Brian, Suzane, 938
`Brichard, Vincent, 944
`Brill, Thomas, 947
`Brown, Christine, 921
`Bruns, Kristina, 959
`Brusa, Davide, 945
`Buchner, Alexander, 947, 948
`Buhtoiarovy,Ilia, 954
`Bui, Jack, 952
`Buller, Mark, 954
`Buonaguro, Franco, 953
`Buonaguro, Luigi, 953
`Burgdorf, Stefan, 951
`Burjanadze, Maka, 930
`Busch, Dirk, 927
`Bushnell, Kathryn, 924
`Butler, Marcus, 921
`Butterfield, Lisa, 939, 942, 946
`Byrd, John, 969
`
`
`Cc
`Calderhead, David, 936
`Campos-Vallete, Marcelo, 954
`Cannon, Martin, 940
`Cantley, Lewis, 931
`Carbone, Michele, 932, 962
`Carbonell, Denysha, 935, 948
`Cardenas, Elisa, 924
`Carrillo, Mayra, 950
`Carroll, Kyla, 950
`Carson, William. 929, 97]
`Castro, Miguel, 944
`Chang, Ken, 955
`Chang, Wen-Chung, 923, 926
`Chapman, Robert, 945
`Cheang, Ellen, 945, 948
`Chen, Hong, 960
`Chen, Huiming, 940
`Chen, Janet, 966
`Chen, Nanhai, 954
`Chen, Xiaochuan, 955
`Chester, John, 952
`Cheung, H Kam, 937
`Chiarion-Sileni, Vanna, 937, 944
`Chiorino, Giovanna, 945
`Chodon, Thinle, 922
`Choi, Hye Kyoung, 958
`
`Chong, Han Toh, 951
`Chu, N, 936
`Chu, Ray, 938
`Claesson, Mogens, 951
`Clay, Timothy, 945
`Coche, Thierry, 944
`Coffey, Matt, 951
`Comin-Anduix, Begonya, 922
`Comins, Charlie, 951
`Connor, Joseph, 964, 970
`Cornforth, Andrew, 922, 935
`Coukos, George, 963
`Curry, Dyan, 948
`Curti, Brendan, 928
`Czystowska, Malgorzata, 957,
`958, 960, 961]
`
`D
`
`Dafferner, Alicia, 967
`Dal Pozzo, Katie, 945, 948
`Daley, Heather, 921
`Davis, Thomas, 945
`De Bono, Johann, 952
`De Ioannes, Alfredo, 954
`De Ioannes, Pablo, 954
`De Pril, Veerle, 937
`DeBenedette, Mark, 936
`Del Campo, Miguel, 954
`Deleayre, Alain, 945, 948
`DePriest, Carol, 922
`DeRaffele, Gail, 965
`Derhovanessian, Evelyna, 962
`Dermime. Said, 963
`Dhungel, Kalpana, 952
`DiGiusto, David. 926
`Dillman, Robert, 922, 935, 948
`Dodds, Michael, 928
`Dogra, Ritika, 940
`Dongmei, He, 928, 929
`Donkor, Moses, 967
`Donze, Olivier, 930
`Doty, Daniel, 956
`Drury, Linda, 921
`Dreno, Brigitte, 944
`Duma, Christopher, 922
`Dumitrascu, Rio, 961
`
`E
`
`Eckert, Helmut, 944
`Edington, Howard, 942
`Eggermont, Alexander, 944
`Egilmez, Nejat, 964
`Eisele, Bernd, 947
`Ellis, Robin, 922
`Ellson, Christopher, 931
`Engleman, Edgar, 949
`Enstrom, Amanda, 944
`Epstein, Alan, 933
`Ernstoff, Marc, 931, 956, 958
`Esuvaranathan, Kesavan,
`931,
`966
`
`Etto, Tamara. 923
`Eubank, Tim, 934
`Evrensel, Cahit, 939
`
`F
`
`Facciabene, Andrea, 963
`Fahmy, Tarek, 949
`Fairchild, Robert, 963
`Falo, Jr, Louis, 966
`Falus, Andras, 930
`Fanyan, Zou, 928
`Felder, Mildred, 964, 970
`Feltquate, D, 956
`Fend, Falko, 947
`Ferreira, Jorge, 954
`Ferris, Robert, 940, 957, 970
`Ferrone, Soldano, 927
`Fiammenghi, Laura, 935
`Figueiredo, Jose-Luiz, 931
`Filippou, Pauline, 960
`Flavell, Richard, 949
`Flavin, Marisa, 921
`Floyd, Kevin, 924
`Foon, Kenneth, 961
`Forget, Marie-Andrée, 963
`Forman, Daron, 956
`Fowler, Abner, 935, 948
`Fox, Bernard. 924
`Francisco, Marites, 938
`Frankenberger, Bernhard, 927,
`932, 948, 967
`Franzoso, Guido, 932
`Friedlander, Philip, 921
`Fuchs, Alan, 939
`Fujisawa, Toshimi, 926,
`Fujisawa, Toshio, 941
`Fulbright, Orenthial, 924
`
`
`G
`
`Gajewski, Thomas, 937, 968, 969
`Gallardo, Humilidad, 934
`Galli, Rossella, 927
`Gallo, Robert, 953
`Gamble, Alicia, 936
`Gannon, Philippe, 963
`Gansbacher, Bernd, 947
`Garetto, Stefano, 945
`Gargano, Michele, 955, 956
`Gaulis, Swann, 944
`Gerloni, Mara, 948
`Ghebeh, Hazem, 963
`Ghiasi, Somayeh, 937
`Gillies, Stephen, 971
`Ginestier, C, 928
`Gnjatic, Sacha, 934
`Godin-Ethier, Jessica. 963
`Goldberg, S, 956
`Goldenberg, David, 955
`Goldrath, Ananda, 960
`Gonzalez, Marissa, 924
`Gooding, William, 957, 970
`
`J] Immunother * Volume 31, Number 9, November-December 2008
`Miltenyi Ex. 1017 Page 8
`
`Miltenyi Ex. 1017 Page 8
`
`

`

`| Immunother * Volume 31, Number 9, November—December 2008
`
`Gorbachev, Anton, 963
`Gordon, Michael, 928
`Gore, Martin, 952
`Gorelik, Elieser, 958
`Granato, Anna Maria, 935
`Gray, Andrew, 941
`Gregory, Melissa, 938
`Grimminger, Friedrich, 961
`Groiss, Franz, 944
`Gruber, Thomas, 941
`Gruenaug, Sabine, 941]
`Gruselle, Olivier, 944
`Gu, Tao, 964
`Gubbels, Jennifer A. 964, 970
`Guenterberg, Kristan, 929
`Guild, Justin, 956
`Gulati, Reema, 956
`Guragain, Sita, 952
`
`H
`
`Haddad, Philip, 929
`Hadrup, Sine, 940
`Hahn, Tobias, 937
`Hall, Geoff, 952
`Halstenson, Charles, 955, 956
`Hamid, Omid. 933, 970
`Han, Tae Hee, 935
`Hanafi, Laila-Aicha, 963
`Hank, Jackie, 970
`Hansen, Michael, 947
`Harding, Thomas, 937
`Harrington, Kevin, 951, 952
`Hartung. Rudolf, 947
`He, Xianghui, 958
`Healey, Don, 936
`Hedley, Mary Lynne, 945
`Heinemann, Lucy, 951
`Heo, Dae Seog, 961
`Hernandez, Claudia, 931, 966
`Hernandez, Jessica, 923
`Hilldorfer, Benedict, 958, 961
`Hinz, Thomas, 953
`Hirano, Naoto, 921
`Hodi, F Stephen, 921, 956
`Hofler, Heinz, 967
`Hofstetter, Alfons, 948
`Hoji, Aki, 928
`Hoke, Traci, 967
`Holden, Helen, 964, 970
`Hoos, Axel, 937
`